Stock NTRP NEUROTROPE, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Neurotrope, Inc.

Equities

NTRP

US64129T2078

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Neurotrope, Inc. completed the spin-off of Neurotrope Bioscience, Inc.
CI
Metuchen Pharmaceuticals LLC completed the acquisition of Neurotrope, Inc. from Intracoastal Capital LLC and others in a reverse merger transaction.
CI
NEUROTROPE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
NEUROTROPE, INC. : Other Events (form 8-K)
AQ
NEUROTROPE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
CI
Neurotrope, Inc Announces Dosing of the First Patient in Its Ongoing, Long-Term Phase 2 Study of Bryostatin-1 for the Treatment of Alzheimer's Disease
CI
NEUROTROPE, INC. : Other Events (form 8-K)
AQ
NEUROTROPE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
CI
NEUROTROPE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
NEUROTROPE, INC. : Other Events (form 8-K)
AQ
NEUROTROPE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
Neurotrope : Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute Trial for Childhood Leukemia
AQ
NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020
CI
Bryologyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1
CI
NEUROTROPE, INC. : Regulation FD Disclosure, Other Events (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NTRP Stock
  4. News Neurotrope, Inc.